Amgen: Cardiovascular Diseases trials
The registry lists 15 Cardiovascular Diseases studies with Amgen as lead sponsor. 2 are open to participants now and 7 have results posted.
Phase 1 6Phase 2 2Phase 3 4Phase 4 2No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography TrialRecruitingNCT07293260Phase 3
- OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And Lipoprotein(a) Reduction to Prevent First Major Cardiovascular EventsRecruitingNCT07136012Phase 3
- Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding StudyCompletedNCT04270760Phase 2Results posted
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AMG 890 in Subjects With Elevated Plasma Lipoprotein(a)CompletedNCT03626662Phase 1Results posted
- Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 986 Administered Orally to Healthy Volunteers and Participants With Severely Impaired Renal FunctionCompletedNCT03318809Phase 1Results posted
- Study to Evaluate the Safety and Tolerability of AMG 986 in Healthy Volunteers and Heart Failure PatientsTerminatedNCT03276728Phase 1Results posted
- Treadmill Cardiovascular Safety Study of Erenumab (AMG 334)CompletedNCT02575833Phase 2Results posted
- ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving HemodialysisCompletedNCT00379899Phase 4Results posted
- RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure TrialCompletedNCT00358215Phase 3Results posted
- A Study to Assess the Mass Balance Recovery (Absorption, Distribution, Metabolism and Excretion) of [14C]CCX168 in Healthy ParticipantsCompletedNCT06004960Phase 1
- A Study in Healthy Volunteers to Evaluate the Pharmacokinetic Food Effect and Cardiac Safety of CCX168CompletedNCT05988021Phase 1
- A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CCX168 in Healthy ParticipantsCompletedNCT05984251Phase 1
- EVOLVE-MI: EVOLocumab Very Early After Myocardial InfarctionActive, not recruitingNCT05284747Phase 4
- Evolocumab Pregnancy Exposure RegistryTerminatedNCT02957604
- An Exploratory Sub-study for the RED-HF™ (Reduction of Events With Darbepoetin Alfa in Heart Failure) TrialTerminatedNCT00534456Phase 3